RIBOSOMAL RNAS 2'O-METHYLATION AS A NOVEL SOURCE OF BIOMARKERS RELEVANT FOR DIAGNOSIS, PROGNOSIS AND THERAPY OF CANCERS

The present invention relates to a method for identifying potentially relevant markers in cancer diagnosis, prognosis and/or therapy, comprising an analysis approach which is based on the detection of variations in methylation of ribosomal RNAs in a biological sample. The present invention also rela...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Hauptverfasser:	MARCEL-TERRIER, VIRGINIE, DIAZ, JEAN-JACQUES, CATEZ, FREDERIC, KIELBASSA, JANICE
Format:	Patent
Sprache:	eng ; fre
Schlagworte:	BEER BIOCHEMISTRY CHEMISTRY COMPOSITIONS OR TEST PAPERS THEREFOR CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL ORENZYMOLOGICAL PROCESSES ENZYMOLOGY MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEICACIDS OR MICROORGANISMS METALLURGY MICROBIOLOGY MUTATION OR GENETIC ENGINEERING PROCESSES OF PREPARING SUCH COMPOSITIONS SPIRITS VINEGAR WINE
Online-Zugang:	Volltext bestellen
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	The present invention relates to a method for identifying potentially relevant markers in cancer diagnosis, prognosis and/or therapy, comprising an analysis approach which is based on the detection of variations in methylation of ribosomal RNAs in a biological sample. The present invention also relates to several applications of this analysis approach for determining the cancer subtype and/or the prognosis of a patient suffering from cancer, for estimating or assessing the benefit of a treatment in such patient, but also for selecting one or more therapeutic drug(s) targeting ribosomes useful for treating cancers. La présente invention concerne un procédé d'identification de marqueurs potentiellement pertinents dans le diagnostic, le pronostic et/ou la thérapie contre le cancer, comprenant une approche d'analyse fondée sur la détection de variations de la méthylation des ARN ribosomiques dans un échantillon biologique. La présente invention concerne également plusieurs applications de cette approche d'analyse pour déterminer le sous-type de cancer et/ou le pronostic d'un patient souffrant d'un cancer, pour estimer ou évaluer le bénéfice d'un traitement chez un tel patient, mais aussi pour sélectionner un ou plusieurs médicament thérapeutique ciblant les ribosomes utiles pour le traitement des cancers.